<DOC>
	<DOCNO>NCT02122809</DOCNO>
	<brief_summary>The purpose dose-escalation study assess safety tolerability treatment Chiauranib administer orally range dos patient advance solid tumor .</brief_summary>
	<brief_title>Phase I Study Chiauranib Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The purpose study assess tolerability safety include adverse event , vital sign , laboratory test , etc. , range dos Chiauranib solid tumor patient , determine dose limit toxicity maximum tolerable dose .</detailed_description>
	<criteria>1 . Histological cytological confirmation advance solid tumor , include nonsmall cell lung cancer , colorectal cancer , ovarian cancer , renal cell carcinoma , gastrointestinal stromal tumor , gastric cancer , et al ; 2 . Patients advance solid tumor refractory standard therapy standard therapy exist ; 3 . Body mass index ( BMI ) 18 28 ; 4 . Age : 18~65 year ; 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 ; 6 . Laboratory criteria follow : 1 . Complete blood count : hemoglobin ( Hb ) ≥100g/L ( blood transfusion within 14 day ) ; absolute neutrophil count ( ANC ) ≥1.5×109/L ; platelet &gt; =100×109/L 2 . Biochemistry test : serum creatinine &lt; =1.5×upper limit normal ( ULN ) ; total bilirubin≦1.5×ULN ; alanine aminotransferase / aspartate aminotransferase≦1.5×ULN ; fast triglyceride ( TG ) &lt; = 3.0 mmol/L ; total cholesterol &lt; = 7.75 mmol/L 3 . Coagulation test : International Normalized Ratio ( INR ) &lt; 1.5 7 . Women childbearing potential nonlactating patient , must agree use effective contraceptive method prior study entry , study participation , 6 month follow completion therapy . A serum urine pregnancy test within 7 day enrollment must negative ; Men must agree use effective contraceptive method study participation 6 month follow completion therapy ; 8 . Willingness sign write informed consent document 1 . Life expectation &lt; 3 month ; 2 . Subjects receive anticancer therapy ( include chemotherapy , radiotherapy , target therapy endocrine therapy , et al ) within 4 week prior study entry ; Subjects receive nitrosoureas mitomycin chemotherapy within 6 week prior study entry ; 3 . Have uncontrolled significant cardiovascular disease , include : 1 . Myocardial infarction ( &lt; last 12 month ) 2 . Uncontrolled angina ( &lt; last 6 month ) 3 . Congestive heart failure ( &lt; last 6 month ) , Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % prior study entry 4 . History significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , TdP ) 5 . History significant QT interval prolongation , Corrected QT Interval ( QTc ) &gt; 450 m prior study entry 6 . History cerebrovascular accident 7 . Symptomatic coronary heart disease require treatment agent 8 . Uncontrolled hypertension ( &gt; 140/90 mmHg ) single agent ; 4 . Have active bleeding , current thrombotic disease , patient bleed potential receiving anticoagulation therapy ; 5 . History deep vein thrombosis pulmonary embolism ; 6 . Have unsolved toxicity ( &gt; grade 1 ) prior anticancer therapy ; 7 . Have clinical significant gastrointestinal abnormality , e.g. , unable swallow , chronic diarrhea , ileus , would impair ingestion , transportation absorption oral agent , patient undergone gastrectomy ; 8 . Have symptomatic brain metastasis ; 9 . History organ transplantation ; 10 . Proteinuria positive ; 11 . Congenital acquire immunodeficiency , active infection ; 12 . Any mental cognitive disorder , would impair ability understand inform consent document operation compliance study ; 13 . Any condition inappropriate study opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chiauranib , advance solid tumor , phase 1 study</keyword>
</DOC>